SCHEMBL6099052

SCHEMBL6099052

Brc1ccccc1OCCCOC1CCCCO1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
MEN1 O00255 2/20 0.49
KDM4C Q9H3R0 1/20 0.48
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
KDM4E B2RXH2 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HPGD P15428 3/20 0.41
HTT P42858 2/20 0.41
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
MAPT P10636 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTR7 P34969 1/20 0.40
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345450 0.93 KDM4C (0.49) KMT2AMEN1KDM4CALDH1A1LMNA
SCHEMBL11168223 0.85 MEN1 (0.44) KMT2AMEN1KDM4CALDH1A1LMNA
SCHEMBL31013566 0.82 MEN1 (0.46) KMT2AMEN1KDM4CALDH1A1LMNA
SCHEMBL8350940 0.82 MEN1 (0.50) KMT2AMEN1KDM4CALDH1A1L3MBTL1
SCHEMBL6095923 0.82 MEN1 (0.44) KMT2AMEN1KDM4CALDH1A1L3MBTL1
SCHEMBL5249245 0.82 KMT2A (0.50) KMT2AMEN1KDM4CALDH1A1LMNA
SCHEMBL28619035 0.81 MEN1 (0.52) KMT2AMEN1KDM4CALDH1A1KDM4E
SCHEMBL29234119 0.81 MEN1 (0.46) KMT2AMEN1KDM4CALDH1A1LMNA
SCHEMBL3446617 0.79 MEN1 (0.46) KMT2AMEN1KDM4CALDH1A1L3MBTL1
SCHEMBL5248504 0.79 MEN1 (0.47) KMT2AMEN1KDM4CALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184669-A Macrocyclic compounds as multi-target kinase inhibitors 北京伯汇生物技术有限公司 2024-06-14 CN disclosed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF KMT2A 4393/4885MEN1 575/4885KDM4C 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.